To systematically analyze the clinical characteristics and efficacy evaluation methods of comorbid ischemic stroke and coronary heart disease.Methods:Relevant literature on comorbid ischemic stroke and coronary heart disease from January 1990 to September 2023 was retrieved from the China National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Sci-tech Journal Database(CCD)，as well as PubMed，ScienceDirect，and Web of Science.Clinical information and evaluation indicators were collected，and frequency statistical analysis was used to summarize the clinical features and efficacy evaluation methods of comorbid ischemic stroke and coronary heart disease.Results:A total of 168 articles were included，consisting of 10 theoretical discussion articles and 158 clinical research articles，with 8 287 patients involved.The clinical symptoms of comorbid ischemic stroke and coronary heart disease，ranked by frequency，were hemiplegia(58.67%)，chest pain(55.40%)，fatigue(38.89%)，dizziness(37.10%)，and facial droop(36.94%).The distribution of syndrome elements included blood stasis(23.53%)，phlegm-dampness(22.58%)，qi deficiency(17.97%)，and yin deficiency(15.10%).Compared with single diseases，comorbid ischemic stroke and coronary heart disease showed significant differences in clinical physicochemical indicators such as blood lipids(20%)，blood pressure(18.67%)，and blood glucose(8%).Common efficacy evaluation indicators in clinical studies included the improvement of primary symptoms(64.58%)，total cholesterol(47.92%)，and neurological deficit scores(25.00%).Conclusion:Comorbid ischemic stroke and coronary heart disease exhibit unique clinical characteristics，including specific symptoms，syndrome elements，primary syndromes，and physicochemical indicators.The efficacy evaluation methods mainly focus on the improvement of primary symptoms.